Topical Use of Valproic Acid for the Prevention or Treatment of Skin Disorders

Abstract

The present invention relates to a topically applicable formulation containing Valproic Acid or a derivative thereof which can be used alone or in combination with topically applicable formulations of retinoids or of nuclear receptor ligands, or of chemotherapeutic agents (e.g. 5-Fluorouracil). The formulation is useful for the topical treatment of cancerous skin disorders, such as Basal Cell Carcinoma, Squamous Cell Carcinoma, Keratoakantoma, Bowen Disease, cutaneous T-Cell Lymphoma and also for the topical treatment of pre-malignant lesions, and of inflammations of the skin and/or mucosa. The invention also relates to the use of this topically applicable formulation for the protection from UV light and for the treatment of sun burn. The invention includes the use of VPA for the manufacture of a clinically used medicament for the topical treatment of the human diseases listed above.

Description

[0001] This application claims priority under 35 U.S.C. §119 to European Patent Application No. 03014278.0, which was filed on Jun. 25, 2003, and under 35 U.S.C. §120 to PCT / EP2004 / 006789, which was filed Jun. 23, 2004, the entirety of which is hereby incorporated by reference. Also, the Sequence Listing on compact disk filed herewith is hereby incorporated by reference (File name: 033-005 Seq List; File size: 4 KB; Date recorded: Dec. 21, 2005).BACKGROUND OF THE INVENTION [0002] 1. Field of the Invention [0003] The present invention relates to a topically applicable formulation containing Valproic Acid or a derivative thereof which can be used alone or in combination with topically applicable formulations of retinoids or of nuclear receptor ligands, or of chemotherapeutic agents (e.g. 5-Fluorouracil). The formulation is useful for the topical treatment of cancerous skin disorders, such as Basal Cell Carcinoma, Squamous Cell Carcinoma, Keratoakantoma, Bowen Disease, cutaneous T-Cell...

AI Technical Summary

Problems solved by technology

In the case of histone hyperacetylation, changes in electrostatic attraction for DNA and steric hindrance introduced by the hydrophobic acetyl group leads to destabilisation of the interaction of histones with DNA.

The great drawback to RA, however, is that it requires high levels of the medication in order to turn genes ‘on’ and ‘off,’ often triggering devastating and potentially fatal side effects (Altucci and Gronemeyer, 2001, Nature Reviews Cancer 1, 181-193).

The results of treatment are not immediate and may be visible only after weeks to months.

Discontinuation of treatment usually results in a loss of RA effects.

However, today more women are getting BCC's than in the past; nonetheless, men still outnumber them greatly.

Those whose occupations require long hours outdoors or who spend extensive leisure time in the sun are in particular jeopardy.

This neoplasm is locally invasive and can be very destructive causing the loss of an eye, ear, or a nose, and may be lethal if it invades the b

Images